Skip to main content
Caplight Logo









Mandeville Therapeutics

Mandeville Therapeutics

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://www.mandevilletx.com/

Last Round

Accelerator

Feb 10, 2026

Total Funding Raised

$100,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Mandeville Therapeutics is a biotechnology company developing small-molecule therapies for the treatment of chronic kidney disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule therapeuticschronic kidney diseaseCKDdrug developmentendothelin receptorbiotech startupnephrologydrug discoverytranslational medicinepharma licensingpre-clinicaltherapeutic pipelinebiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mandeville Therapeutics Comparables

Compare Mandeville Therapeutics with similar companies based on industry and business-model similarity.

Mandeville Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioCity Biopharma
87%
R1 Therapeutics
82%
AstraZeneca
74%

Mandeville Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorFeb 10, 2026

Mandeville Therapeutics Investors

Notable investors and investment history

Mandeville Therapeutics investors
InvestorRounds
AlphaLabAccelerator
Innovation WorksAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 10, 2026

    $100K round led by AlphaLab

Mandeville Therapeutics Filings

Explore SEC and related filing metadata, where available.

Mandeville Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Mandeville Therapeutics's valuation, stock price, and market status.

Is Mandeville Therapeutics a public or private company?

Mandeville Therapeutics is a private company.

What is the current stock price of Mandeville Therapeutics?

Mandeville Therapeutics is a private company with no public stock price. Caplight tracks Mandeville Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Mandeville Therapeutics worth (valuation)?

Valuation information for Mandeville Therapeutics is not publicly available.

Can I buy Mandeville Therapeutics stock?

Mandeville Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Mandeville Therapeutics's last funding round?

Mandeville Therapeutics's most recent funding round was Accelerator on February 10, 2026.

Who are the main investors in Mandeville Therapeutics?

Key investors in Mandeville Therapeutics include AlphaLab.

Will Mandeville Therapeutics IPO soon?

No public IPO plans have been announced for Mandeville Therapeutics.

How can I track Mandeville Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mandeville Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range2
Year Founded2025
Last FundingFeb 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?